Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WJMSC for Osteoarthritis
NCT03866330Phase 2Unknown
- Sponsor
- Medical University of Warsaw
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of wharton's jelly mesenchymal stromal cells in osteoarthritis (OA) (3 arms), sponsored by Medical University of Warsaw. Primary endpoints: Hip Disability and Osteoarthritis Outcome Score at 24 months, Harris Hip Score at 24 months and 7 more. Status: unknown.
02
Drugs
wharton's jelly mesenchymal stromal cells
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03866330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866330.